Four candidate proteins (IL-18, IL-10, TLR5, and DPP10) have been nominated as targets for AD treatment by the AMP-AD (Accelerating Medicine Partnership Program for AD) consortium (Fig. 6c and Supplementary Table 37). This evidence concerns the gene TLR5 and Alzheimer disease.